Your browser doesn't support javascript.
loading
Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study.
Scott, Dr Nick; Palmer, Ms Anna; Tidhar, Mr Tom; Stoove, Prof Mark; Sacks-Davis, Dr Rachel S; Doyle, A/Prof Joseph S; Pedrana, Dr Alisa J; Thompson, Prof Alexander; Wilson, Prof David P; Hellard, Prof Margaret.
Afiliação
  • Scott DN; Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia.
  • Palmer MA; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia.
  • Tidhar MT; Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia.
  • Stoove PM; Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia.
  • Sacks-Davis DRS; Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia.
  • Doyle AJS; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia.
  • Pedrana DAJ; Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia.
  • Thompson PA; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia.
  • Wilson PDP; Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia.
  • Hellard PM; Department of Infectious Diseases, The Alfred and Monash University, Melbourne, VIC 3004, Australia.
Lancet Reg Health West Pac ; 18: 100316, 2022 Jan.
Article em En | MEDLINE | ID: mdl-35024654
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article